Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
|Articles|November 13, 2017
Nitto Avecia Completes Large-Scale Synthesis of Oligonucleotide
Author(s)BioPharm International Editors
Company completes first successful run of what is believed to be the largest synthesis-scale done for oligonucleotide APIs.
Advertisement
Nitto Avecia, a provider of oligonucleotide manufacturing and development services, announced on Nov. 7, 2017 that it had successfully completed the first synthesis runs at the 1.6 Mol-scale, which is believed to be the largest synthesis-scale executed for oligonucleotide active pharmaceutical ingredients (APIs). The run was conducted at its new oligonucleotide manufacturing facility in Milford, MA.
The completed run comes months after the company first brought its new API manufacturing synthesis capabilities on line. This manufacturing capacity expansion increases the company's total synthesis capacity to more than 3 Mol.
Nitto Avecia's President Detlef Rethage stated in a company press release: "Avecia's leadership in the oligonucleotide market is significant, and we are proud to have added this major manufacturing scale in less than two years to address a capacity shortage that could have slowed down our client's clinical trial progress. With our 1.6 Mol synthesis capabilities now operational, the capacity shortage in oligonucleotides manufacturing has now been addressed."
Source:
Advertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5